What is the TNFR-Fc fusion protein?

TNFR-Fc fusion protein is , while it's Molecular Formula is H4NO3V. To decrease signs and symptoms of rheumatoid arthritis.Etanercept (Enbrel) is a soluble TNF receptor fusion protein. It is FDA approved for moderate to severe psoriasis at a dose of 50 mg twice weekly by subcutaneous injection for the initial 12 weeks, followed by a stepdown to 50 mg weekly for maintenance. The most common side effect is injection site reactions. Rare cases of serious infection, demyelinating disease, and congestive heart failure have been reported by postmarketing surveillance.

What is the CAS number for TNFR-Fc fusion protein?

The CAS number of TNFR-Fc fusion protein is 185243-69-0.

What is TNFR-Fc fusion protein (185243-69-0) used for?

Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary mammalian cell lineand is the first biotechnology-derived drug to be introduced for the reduction of the signs and symptoms ofmoderately to severely active rheumatoid arthritis in patients who have not adequately responded to one or more ofthe synthetic DMARDs. It is a dimeric soluble form of the p75 TNFR capable of binding to two TNF molecules in thecirculation. It consists of the extracellular ligand binding portion of the 75-kDa human TNFR fused to the Fc portionof human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain, and thehinge region, but not the CH1 domain of IgG1. It consists of 934 amino acids and has an apparent molecular weightof approximately 150 kDa. Two TNFRs have been identified, a 75-kDa protein and a 55-kDa protein, that occur asmonomeric molecules on cell surfaces and soluble forms in the blood. The biological activity of TNF requires itsbinding to either of the two cell surface TNFRs. Etanercept can bind specifically to two molecules of TNFα in thecirculation, preventing its interaction with cell surface TNFRs.InChI:InChI=1/C4H6N4O12/c9-5(10)17-1-3(19-7(13)14)4(20-8(15)16)2-18-6(11)12/h3-4H,1-2H2/t3-,4+

Product Class

185243-69-0

Product Name：Etanercept
Molecular Formula：H4NO3V
Purity：99%
Molecular Weight：116.97816

Inquiry

Product Details:

CasNo： 185243-69-0

Molecular Formula： H4NO3V

Quality Manufacturer Supply Best Quality Etanercept 185243-69-0 Safe Transportation

Molecular Formula:H4NO3V
Molecular Weight:116.97816
Vapor Pressure:1.09E-05mmHg at 25°C
Boiling Point:381.8°C at 760 mmHg
Flash Point:178.8°C
PSA：0.00000
Density:1.757g/cm³
LogP:0.00000

Etanercept(Cas 185243-69-0) Usage and Manufacturer

Description

Etanercept is a medication used to manage and treat various autoimmune conditions, including plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis. Hangzhou Huarong Pharm Co., Ltd., founded in 2009, is dedicated to providing innovative products and services for small molecule drug discovery and development. The company specializes in research, development, and manufacturing across a range of fields, including Building Blocks, Reference Compounds & Impurities, Natural Products, APIs & Intermediates, and Antibody-drug Conjugates (ADCs). With a focus on R&D, Huarong Pharm has invested heavily in state-of-the-art facilities and GMP-certified plants. It has successfully served over 3,000 partners globally and aims to become a world leader in supporting life science innovation. The company’s core values are responsibility, teamwork, professionalism, efficiency, and continuous growth.

Uses

While etanercept is not classified as a traditional immunosuppressant, it does affect the immune system. By inhibiting TNF-α, etanercept can lower the ability of the immune system to fight infections. This can increase the risk of serious infections, including tuberculosis (TB), as well as infections caused by viruses, fungi, or bacteria that have spread throughout the body. Etanercept works by blocking the effects of TNF-alpha, a pro-inflammatory cytokine that becomes elevated in psoriasis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis.

InChI:InChI=1/C4H6N4O12/c9-5(10)17-1-3(19-7(13)14)4(20-8(15)16)2-18-6(11)12/h3-4H,1-2H2/t3-,4+

185243-69-0 Relevant articles

Etanercept A Review of its Use in Rheumatoid Arthritis

Blair Jarvis & Diana Faulds

Drugs, Volume 57, pages 945–966, (1999)

A dose-response effect was apparent with etanercept 0.25 to 16 mg/m2 twice weekly in a randomised, double-blind study in 180 patients. The mean number of swollen or tender joints at the end of the 12-week study decreased by >50% in patients treated with etanercept 16 mg/m2 twice weekly and by >25% in patients treated with placebo.

Effects of Etanercept in Patients With the Metabolic Syndrome

L. Elizabeth Bernstein, MD; Jacqueline Berry, BA; Sunnie Kim, BA;

Arch Intern Med. 2006;166(8):902-908.

Fifty-six subjects with the metabolic syndrome were randomized to administration of either etanercept or identical placebo, 50 mg subcutaneously once a week for 4 weeks. The C-reactive protein level was the primary end point. Effects on other inflammatory markers (including fibrinogen, interleukin 6, and adiponectin), insulin sensitivity, lipid levels, and body composition were also determined.

Relevant Products

Apixaban
CAS：503612-47-3
Crisaborole（AN2728）
CAS：906673-24-3
Risperidone
CAS：106266-06-2